The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar

Inflammatory Bowel Diseases

Volumn 23, Issue 2, 2017, Pages 233-243

  Fiorino, Gionata ^a   Manetti, Natalia ^b   Armuzzi, Alessandro ^c   Orlando, Ambrogio ^d   Variola, Angela ^e   Bonovas, Stefanos ^a   Bossa, Fabrizio ^f   Maconi, Giovanni ^g   D'Incà, Renata ^h   Lionetti, Paolo ⁱ   Cantoro, Laura ^j   Fries, Walter ^k   Annunziata, Maria L ^l   Costa, Francesco ^m   Terpin, Maria M ⁿ   Biancone, Livia ^o   Cortelezzi, Claudio C ^p   Amato, Arnaldo ^q   Ardizzone, Sandro ^r   Danese, Silvio ^a   Guidi, Luisa ^c   Rizzuto, Giulia ^d   Massella, Arianna ^e   Andriulli, Angelo ^f   Massari, Alessandro ^g   Lorenzon, Greta ^h   Ghione, Silvia ⁱ   Kohn, Anna ^j   Ventra, Agostino ^k   Annese, Vito ^b   Principi, Mariabeatrice ^s   Di Girolamo, Maria ^t   Bertani, Angela ^t   Saettone, Silvia ^u   Tari, Roberto ^u   Petruzzellis, Carlo ^v   Guglielmi, Francesco W ^w   Mazzuoli, Silvia ^w   Cappello, Maria ^x   Viola, Anna ^x   Castiglione, Fabiana ^y   Nardone, Olga ^y   Di Sabatino, Antonio ^z   Saibeni, Simone ^aa   Bezzio, Cristina ^aa   Caserta, Luigi ^ab   Parodi, Maria Caterina ^ab   Meucci, Gianmichele ^ac   Colli, Agostino ⁿ   Ronchetti, Anna ⁿ   Vecchi, Maurizio ^l   Bertani, Lorenzo ^m   Bosani, Matteo A ⁿ   Tronconi, Edoardo ^o   Imperiali, Gianni ^q   Salerno, Raffaele ^r   Rogai, Francesca ^b   Milani, Stefano ^b   Pugliese, Daniela ^c   Renna, Sara ^d   Geccherle, Andrea ^e   Martino, Giuseppina ^f   Cassinotti, Andrea ^g   more..

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^k UNIVERSITY OF MESSINA   (Italy)

^l FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^m UNIVERSITY HOSPITAL OF PISA   (Italy)

ⁿ AO Hospital   (Italy)

^o UNIVERSITY OF ROME TOR VERGATA   (Italy)

^p Laboratory of Endocrinology and Tumor Markers   (Italy)

^q VALDUCE HOSPITAL   (Italy)

^r FATEBENEFRATELLI HOSPITAL   (Italy)

^s UNIVERSITY OF BARI   (Italy)

^t UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^u AOU Maggiore della Carita   (Italy)

^v Fondazione Poliambulanza Istituto Ospedaliero   (Italy)

^w S Pellegrino Hospital   (Italy)

^x UNIVERSITY OF PALERMO   (Italy)

^y UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^z UNIVERSITY OF PAVIA   (Italy)

^aa RHO HOSPITAL   (Italy)

^ab UNIVERSITY OF GENOA   (Italy)

^ac S Giuseppe Hospital   (Italy)

more..

Author keywords

biosimilar; Crohn's disease; CT P13; inflammatory bowel disease; Inflectra; Infliximab; Remsima; ulcerative colitis

Indexed keywords

ADALIMUMAB; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; BIOSIMILAR AGENT; CT-P13; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; COHORT ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CROHN DISEASE; CROHN’S DISEASE ACTIVITY INDEX; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION AND FOLLOW UP; FEMALE; HARVEY BRADSHAW INDEX; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFLAMMATORY BOWEL DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN ALLERGY; ULCERATIVE COLITIS; YOUNG ADULT; FACTUAL DATABASE; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; CROHN DISEASE; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; INFUSIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85010905756     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000995     Document Type: Conference Paper

References (54)

1. Danese S, Vuitton L, Peyrin-Biroulet L. Biological agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545.
2. Annese V, Duricova D, Gower-Rousseau C, et al. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the epidemiology committee of ECCO. J Crohns Colitis. 2016; 10:216-225.
3. van der Valk ME, Mangen MJ, Leenders M, et al; COIN Study Group and the Dutch Initiative on Crohn and Colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut. 2014;63:72-79.
4. Cohen RD, Thomas T. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35: 867-882.
5. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology - " O brave new world". Nat Rev Rheumatol. 2012;8:430-436.
6. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72: 1605-1612.
7. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallelgroup study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613-1620.
8. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. [Published online ahead of print April 29, 2016]. doi: 10.1136/annrheumdis-2015-208786.
9. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016; 18:82.
10. Yoo D, Yagensky A, Toncheva A, et al. Impact of CT-P13 and Originator Infliximab Treatment on Quality of Life Derived from the Health Assessment Questionnaire (AQ) and Short-form 36 (SF-36) from a Randomized, Double-Blind Trial in Patients with Active RA [Abstract No. 2392]. San Diego, CA: ACR/ARHP Annual Meeting; 2013:26-30.
11. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. [Published online ahead of print April 26, 2016]. doi: 10.1136/annrheumdis-2015-208783.
12. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. [Published online ahead of print April 29, 2016]. doi: 10.1136/annrheumdis-2015-208786.
13. McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014;28:313-321.
14. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment Report: Remsima (Infliximab). 2013. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002576/WC500151486.pdf. Accessed October 10, 2016.
15. Generics and biosimilars initiative online. Biosimilars approved in South Korea. 2015. Available at: http://gabionline.net/ Biosimilars/General/Biosimilars-approved-in-South-Korea. Accessed October 10, 2016.
16. Generics and biosimilars initiative online. Biosimilars approved in Japan. 2015. Available at: http://gabionline.net/ Biosimilars/General/Biosimilarsapproved-in-Japan. Accessed October 10, 2016.
17. Available at: www.fda.gov/downloads/./UCM484859.pdf. Accessed October 10, 2016.
18. Health Canada. Summary basis of decision - Inflectra. 2016. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds-sdrinfectra-184564-eng.php. Accessed October 10, 2016.
19. Health Canada. Summary basis of decision - Inflectra. 2014. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd- 2014-inflectra-159493-eng.php. Accessed October 10, 2016.
20. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42: 177-183.
21. Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32:742-756.
22. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014;8:1548-1550.
23. Annese V, Vecchi M; Italian Group for the Study of IBD (IG-IBD). Use of biosimilars in inflammatory bowel disease: statements of the Italian group for inflammatory bowel disease. Dig Liver Dis. 2014;46:963-968.
24. Danese S, Gomollon F. Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7:586-589.
25. Ben-Horin S, Heap GQ, Ahmad T et al. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Exp Rev Gastroenterol Hepatol. 2015; 9(suppl 1):27-34.
26. Van den Brande JM, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut. 2007;56:509-517.
27. Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Exp Opin Biol Ther. 2007;7:1051-1059.
28. Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2014;60:951-956.
29. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastrenterol Hepatol. 2015;30:1705-1712.
30. Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 Treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohn's Colitis. 2016: 133-140.
31. Park SH, Kim YH, Lee JH et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Exp Rev Gastroenterol Hepatol. 2015;9(suppl 1):35-44.
32. Sieczkowskaa J, Jarzȩbickaa D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohn's Colitis. 2016:127-132.
33. Farkas K, Rutka M, Bálint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center. Exp Opin Biol Ther. 2015;15: 1257-1262.
34. Jahnsen J, Detlie TE, Vatn S et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(suppl 1):45-52.
35. Keil R, Wasserbauer M, Zádorová Z, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol. 2016;51:1062-1068.
36. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-16; discussion 6-9.
37. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
38. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
39. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. Engl J Med. 2005;353: 2462-2476.
40. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index [CDAI]. Gastroenterology. 1979;77(4 pt 2):843-846.
41. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;315:514.
42. D'Haens GR, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
43. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
44. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30-51.
45. Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, doubleblind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015 [epub ahead of print].
46. Jani RH, Gupta R, Bhatia G, et al. A prospective, randomized, doubleblind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. [Published online ahead of print July 14, 2016]. doi: 10.1111/1756-185X.12711.
47. Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016; 10:133-140.
48. Golovics PA, Vegh Z, Rutka M, et al. Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibody's or clinical/biochemical markers play a more important role? J Crohns Colitis. 2016;10(suppl 1):S2. OP003.
49. Lovasz B, Kurti Z, Rutka M, et al. Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort. J Crohn Colitis. 2016;10(suppl 1):S46. DOP033.
50. Bettey M, Downey L, Underhill C, et al. Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. J Crohn Colitis. 2016;10(suppl 1):S43-S44. DOP029.
51. Smits L, Derikx L, Drenth J, et al. Elective switching from Remicade to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. Journals Crohns Colitis. 2016;10(suppl 1): S44-S45. DOP030.
52. Kolar M, Duricová D, Brotlik M et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade) to biosimilar infliximab (Remsima) is effective and safe. J Crohns Colitis. 2016;10 (suppl 1):S45-S46. DOP032.
53. Farkas K, Rutka M, Golovics PA, et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis. 2016;10:1273-1278.
54. Murphy C, Sugrue K, Mohamad G, et al. Biosimilar but not the same. J Crohns Colitis. 2014;8(suppl 1):P505.